This is a fascinating long piece about how improving the cost-effectiveness of randomized controlled clinical trials is essential for realizing the full value (& minimizing risks) from the biotech revolution:
https://www.statnews.com/2022/11/03/why-were-not-prepared-for-next-wave-of-biotech-innovation/